Meta Information
ID:bpc-157
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/condition/active-cancer
Target name:
Active Cancer
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 promotes angiogenesis (the formation of new blood vessels), a process which is essential for tumor growth and metastasis. Its use in the presence of active cancer is strongly contraindicated.
Actionable advice:
Avoid completely if you have a current or recent history of cancer.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The effects of BPC-157 on fetal development are unknown. Its influence on growth factors and angiogenesis poses a significant theoretical risk to the developing fetus.
Actionable advice:
Do not use if you are pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown if BPC-157 or its metabolites are excreted into breast milk or what their effects would be on a nursing infant. Use is contraindicated due to unknown risks.
Actionable advice:
Do not use if you are breastfeeding.
Target id:
/class/chemotherapy-radiation
Target name:
Anti-Angiogenic Cancer Drugs
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 promotes angiogenesis, which directly opposes the mechanism of anti-angiogenic therapies (e.g., bevacizumab, sorafenib) and could render them less effective.
Actionable advice:
Avoid completely while on anti-angiogenic cancer therapy.
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157's role in tissue healing and blood vessel formation could theoretically alter coagulation pathways, potentially increasing the risk of bleeding when combined with blood thinners.
Actionable advice:
Use with extreme caution and under medical supervision if taking any blood thinning medication.
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
By modulating the nitric oxide (NO) system, BPC-157 may influence blood pressure, potentially leading to an excessive drop (hypotension) when combined with blood pressure-lowering medications.
Actionable advice:
Monitor blood pressure closely if combining with antihypertensive drugs, especially upon initiation.
Target id:
/class/dopaminergic-agents
Target name:
Dopaminergic Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Animal studies suggest BPC-157 modulates the dopamine system, which could unpredictably alter the effects of medications for Parkinson's disease, antipsychotics, or stimulants.
Actionable advice:
Consult a physician before using if you take any medication that affects dopamine.
Target id:
/dietary/meal
Target name:
Any Caloric Meal (Oral BPC-157)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
2
Description:
For oral formulations, the presence of food and digestive enzymes in the stomach can degrade the peptide, potentially reducing its absorption and systemic effectiveness.
Actionable advice:
Take oral BPC-157 on an empty stomach, at least 1 hour before or 2 hours after a meal.
Target id:
/intervention/tb-500
Target name:
TB-500 (Thymosin Beta-4)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 and TB-500 are often used together as they are thought to have complementary and synergistic effects on tissue repair, inflammation reduction, and wound healing.
Actionable advice:
May be taken together for potentially enhanced healing effects.
Target id:
/class/nsaids
Target name:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Animal studies show BPC-157 can protect against and help repair NSAID-induced gastrointestinal damage, acting as a potent cytoprotective (cell-protective) agent.
Actionable advice:
May be co-administered to potentially mitigate the gastric side effects of NSAIDs.
Target id:
/class/ghrps-ghrhs
Target name:
Growth Hormone Secretagogues (e.g., Ipamorelin, CJC-1295)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 may upregulate growth hormone receptors in tissues, potentially enhancing the tissue-repair signaling and effects of peptides that increase growth hormone release.
Actionable advice:
May be used concurrently for a potentially synergistic effect on recovery and healing.
Target id:
/class/serotonergic-agents
Target name:
Serotonergic Medications (SSRIs, SNRIs, etc.)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Preclinical data suggests a potential influence on the serotonin system, which could theoretically alter the effects or side effects of serotonergic drugs. This interaction is highly speculative.
Actionable advice:
Use with caution and monitor for any mood or behavioral changes if taking serotonergic medications.
Target id:
/class/proton-pump-inhibitors
Target name:
Proton Pump Inhibitors (PPIs)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
By reducing stomach acid, PPIs may increase the stability and subsequent absorption of acid-labile oral BPC-157 formulations, potentially increasing their bioavailability.
Actionable advice:
Taking oral BPC-157 while on PPIs may enhance its absorption.